Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), filed a Form 4 on September 4, 2026, reporting the sale of common stock on September 3, 2026, in connection with the vesting of restricted stock units.

Key Highlights

  • Reporting person: Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc.
  • Shares disposed: 10,366 shares of common stock sold on September 3, 2026, with transaction code "S".
  • Weighted average price: $11.1555 per share, with individual sale prices ranging between $11.0301 and $11.1556.
  • Post-transaction ownership: 283,084 shares of common stock held directly following the reported transaction.
  • Sell-to-cover: According to the filing, the sales were automatic under the issuer's "sell-to-cover" policy to satisfy tax withholding obligations tied to RSU vesting, and were "not at the discretion of the Reporting Person."

RSU Vesting Triggers Automatic Share Sale for Artiva Biotherapeutics Executive

According to the Form 4 filed with the SEC, Christopher Horan, serving as Chief Tech Operations Officer at Artiva Biotherapeutics, Inc., disposed of 10,366 shares of common stock on September 3, 2026. The filing identifies the transaction code as "S," indicating an open-market sale. The shares were sold at a weighted average price of $11.1555, with the range of individual transaction prices spanning from $11.0301 to $11.1556 per share.

The filing notes that the sale was carried out under the issuer's "sell-to-cover" policy, which the company has adopted to satisfy tax withholding obligations arising from the vesting and release of restricted stock units. The filing states explicitly that such sales were "automatic and not at the discretion of the Reporting Person." The filing further states that full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder.

Following the reported transaction, Horan directly beneficially owned 283,084 shares of Artiva Biotherapeutics common stock, according to the filing. The Form 4 was signed by Andrew Cronauer as attorney-in-fact and was filed on September 4, 2026.

What Was Disclosed

The filing reported a single disposition of 10,366 shares of Artiva Biotherapeutics common stock by Chief Tech Operations Officer Christopher Horan on September 3, 2026, executed automatically under the company's sell-to-cover policy for RSU tax withholding, at a weighted average price of $11.1555 per share.